Image source: stockmonkeys.com via Flickr.
Guess what? The FDA approved Gilead Sciences (NASDAQ: GILD) newest hepatitis C drug, Epclusa, earlier this week. Not surprised? You’re not alone. After delivering 98% cure rates and arguably best-in-class safety in trials, just about everyone believed the FDA would give Epclusa a green light.